Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer

Endocrine-Related Cancer

Volumn 20, Issue 3, 2013, Pages

  Bitting, Rhonda L ^a   Armstrong, Andrew J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Akt; Androgen receptor signaling; Castration resistant prostate cancer (CRPC); Combination therapy; MTOR; PI3K inhibitors; PI3K pathway

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ABIRATERONE ACETATE; APITOLISIB; AZD 2014; BICALUTAMIDE; BUPARLISIB; DS 3078A; ENZALUTAMIDE; EVEROLIMUS; EXEMESTANE; GDC 0068; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MLN 0128; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PICTILISIB; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RIDAFOROLIMUS; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 147;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANGIOGENESIS; ANOREXIA; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; APOPTOSIS; BLOOD BRAIN BARRIER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CYTOSTASIS; DECREASED APPETITE; DEPRESSION; DIARRHEA; DYSGEUSIA; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERGLYCEMIA; KIDNEY METASTASIS; MAXIMUM TOLERATED DOSE; MOLECULARLY TARGETED THERAPY; MOOD DISORDER; NAUSEA; NONHUMAN; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN SYNTHESIS; RASH; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VOMITING;

AKT; ANDROGEN RECEPTOR SIGNALING; CASTRATION-RESISTANT PROSTATE CANCER (CRPC); COMBINATION THERAPY; MTOR; PI3K INHIBITORS; PI3K PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84879478480     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0394     Document Type: Review

References (128)

1. Ackermann TF, Hortnagl H, Wolfer DP, Colacicco G, Sohr R, Lang F, Hellweg R & Lang UE 2008 Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cellular Physiology and Biochemistry 22 735-744. (doi:10.1159/000185557)
2. Amato RJ, Jac J, Mohammad T & Saxena S 2008 Pilot study of rapamycin in patients with hormone-refractory prostate cancer. Clinical Genitourinary Cancer 6 97-102. (doi:10.3816/CGC.2008.n.015)
3. Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R et al. 2010 A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clinical Cancer Research 16 3057-3066. (doi:10.1158/1078-0432.CCR-10-0124)
4. Armstrong AJ, Marengo MS, Oltean S, Kemeny G, Bitting RL, Turnbull JD, Herold CI, Marcom PK, George DJ & Garcia-Blanco MA 2011 Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Molecular Cancer Research 9 997-1007. (doi:10.1158/1541-7786. MCR-10-0490)
5. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R et al. 2009 Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Research 69 2912-2918. (doi:10.1158/0008-5472.CAN-08-3667)
6. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T & Harper W 2004 High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clinical Cancer Research 10 6572-6578. (doi:10.1158/1078-0432.CCR- 04-0477)
7. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F et al. 2012 Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine 366 520-529. (doi:10.1056/NEJMoa1109653)
8. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA & Ghosh PM 2007 Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clinical Cancer Research 13 3860-3867. (doi:10.1158/1078-0432.CCR-07-0091)
9. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters Met al. 2012 Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Journal of Clinical Oncology 30 282-290. (doi:10.1200/JCO. 2011.36.1360)
10. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M & Tannock IF 2008 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. Journal of Clinical Oncology 26 242-245. (doi:10.1200/JCO. 2007.12.4008)
11. Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante J, Silva A, Demanse D, Hackl W & Baselga J 2010 First-in-man phase I study of the oral dual PI3K and mTORC1/2 inhibitor BEZ235 in patients with advanced solid tumors. Journal of Clinical Oncology 28 abstract 3005.
12. Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM & Siu LL 2012 Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. Journal of Clinical Oncology 30 2919-2928. (doi:10.1200/JCO.2011.39.7356)
13. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC et al. 2008 Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation 118 3065-3074.
14. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H et al. 2011 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19 575-586. (doi:10.1016/j.ccr.2011.04.008)
15. Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR et al. 2007 The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clinical Genitourinary Cancer 5 433-437. (doi:10.3816/CGC. 2007.n.031)
16. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33-39. (doi:10.1038/nm972)
17. Chen Y, Sawyers CL & Scher HI 2008 Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology 8 440-448. (doi:10.1016/j.coph.2008.07.005)
18. Courtney KD, Corcoran RB & Engelman JA 2010 The PI3K pathway as drug target in human cancer. Journal of Clinical Oncology 28 1075-1083. (doi:10.1200/JCO.2009.25.3641)
19. Dash A, Maine IP, Varambally S, Shen R, Chinnaiyan AM & Rubin MA 2002 Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. American Journal of Pathology 161 1743-1748. (doi:10.1016/S0002-9440(10)64451-3)
20. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ & Raghavan D 2008 Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 14 6302-6309. (doi:10.1158/1078-0432. CCR-08-0872)
21. De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L et al. 2010 Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 1147-1154. (doi:10.1016/S0140-6736(10)61389-X)
22. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F et al. 2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995-2005. (doi:10.1056/NEJMoa1014618)
23. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA et al. 2012 The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486 537-540.
24. Dibble CC, Asara JM & Manning BD 2009 Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Molecular and Cellular Biology 29 5657-5670. (doi:10.1128/MCB. 00735-09)
25. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R et al. 2011 SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470 269-273. (doi:10.1038/nature09677)
26. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG & Reddy VA 2009 The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. PNAS 106 268-273. (doi:10.1073/pnas.0810956106)
27. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, Watson J, Sauveur-Michel M, Garcia-Echeverria C, Cho CY et al. 2010 Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clinical Cancer Research 16 5692-5702. (doi:10.1158/1078-0432.CCR- 10-1601)
28. Edelman G, Bedell C, Shapiro G, Pandya S, Kwak E, Scheffold C, Nguyen L, Laird A, Baselga J & Rodon J 2010 A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. Journal of Clinical Oncology 28 abstract 3004.
29. Edgar KA, Wallin JJ, Berry M, Lee LB, Prior WW, Sampath D, Friedman LS & Belvin M 2010 Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Research 70 1164-1172. (doi:10.1158/0008-5472.CAN-09-2525)
30. Fang Z, Zhang T, Dizeyi N, Chen S, Wang H, Swanson KD, Cai C, Balk SP & Yuan X 2012 Androgen receptor enhances p27 degradation in prostate cancer cells through rapid and selective TORC2 activation. Journal of Biological Chemistry 287 2090-2098. (doi:10.1074/jbc.M111.323303)
31. Festuccia C, Gravina GL, Muzi P, Millimaggi D, Dolo V, Vicentini C & Bologna M 2008 Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate 68 965-974. (doi:10.1002/pros.20757)
32. Floryk D & Thompson TC 2008 Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Letters 266 216-226. (doi:10.1016/j.canlet.2008.02.060)
33. Fritsch CM, Schnell C, Chatenay-Rivauday C, Guthy DA, De Pover A, Wartmann M, Brachmann S, Maira S, Huang A, Quadt C, et al. 2012 NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent. In Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR abstract 3748.
34. Fung AS, Wu L & Tannock IF 2009 Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clinical Cancer Research 15 5389-5395. (doi:10.1158/1078-0432.CCR-08-3007)
35. Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA et al. 2010 eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. PNAS 107 14134-14139. (doi:10.1073/pnas.1005320107)
36. George DJ, Armstrong AJ, Creel P, Morris K, Madden J, Turnbull J, Dewhirst M, Major N & Febbo PG 2008 A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC). Genitourinary Cancers Symposium abstract 181.
37. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P et al. 2012 Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine 366 883-892.
38. Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkuhle JD, Petricoin EF, Conaway M & Weber MJ 2011 Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer. Molecular Cancer Therapeutics 10 1581-1590. (doi:10.1158/1535-7163.MCT-10-1033)
39. Glickman MS & Sawyers CL 2012 Converting cancer therapies into cures: lessons from infectious diseases. Cell 148 1089-1098. (doi:10.1016/j.cell.2012. 02.015)
40. Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K & Agus DB 2007 A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7 142. (doi:10.1186/1471-2407-7-142)
41. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB & Hidalgo M 2002 Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Research 62 6141-6145.
42. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M et al. 2002 Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nature Medicine 8 128-135. (doi:10.1038/nm0202-128)
43. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H & Sabatini DM 2009 mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 15 148-159. (doi:10.1016/j.ccr.2008. 12.017)
44. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, Shi EY, Stumpf CR, Christensen C, Bonham MJ et al. 2012 The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485 55-61. (doi:10.1038/nature10912)
45. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL & Powis G 2009 Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Research 69 143-150. (doi:10.1158/0008-5472.CAN-07-6656)
46. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek V, Fu S, Piha-Paul SA, Lee JJ & Luthra R 2012 PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early phase clinical trials. Cancer Research 73 276-284. (doi:10.1158/0008-5472.CAN-12-1726)
47. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
48. Jessen K, Kessler L, Kucharski J, Guo X, Staunton J, Janes M, Elia M, Banerjee U, Lan L, Wang S et al. 2011 A potent and selective PI3K inhibitor, INK1117, targets human cancers harboring oncogenic PIK3CA mutations. Molecular Cancer Therapeutics 10 Abstract A171. (doi:10.1158/1535-7163.TARG-11-A171)
49. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM et al. 2008 Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454 776-779.
50. Jia S, Roberts TM & Zhao JJ 2009 Should individual PI3 kinase isoforms be targeted in cancer? Current Opinion in Cell Biology 21 199-208. (doi:10.1016/j.ceb.2008.12.007)
51. Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ & Roberts TM 2013 Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discovery 3 44-51. (doi:10.1158/2159-8290.CD-12-0262)
52. Jimeno A, Herbst RS, Falchook GS, Messersmith WA, Hecker S, Peterson S, Hausman DF, Kurzrock R, Eckhardt SG & Hong DS 2010 Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. Journal of Clinical Oncology 28 abstract 3089.
53. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB et al. 2010 Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine 363 411-422. (doi:10.1056/NEJMoa1001294)
54. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C et al. 2008 Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. Journal of Clinical Investigation 118 3051-3064.
55. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S & Ghosh PM 2004 Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Research 64 5232-5236. (doi:10.1158/0008-5472.CAN-04-0272)
56. Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R & Pazdur R 2010 FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 15 428-435. (doi:10.1634/ theoncologist.2009-0178)
57. Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X & Wu H 2006 NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9 367-378. (doi:10.1016/j.ccr.2006.03.031)
58. Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, leisher M et al. 2009 Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clinical Cancer Research 15 2091-2097. (doi:10.1158/1078-0432.CCR-08-2036)
59. Li Y, Wang Z, Kong D, Li R, Sarkar SH & Sarkar FH 2008 Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. Journal of Biological Chemistry 283 27707-27716. (doi:10.1074/jbc. M802759200)
60. Lim M, Chuong CM & Roy-Burman P 2011 PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Hormones & Cancer 2 298-309. (doi:10.1007/s12672-011-0084-4)
61. Lin K 2011 GDC-0068: a novel, selective, ATP-competitive inhibitor of Akt. In Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, Florida. Philadelphia (PA): AACR abstract DDT02-01.
62. Lin HK, Yeh S, Kang HY & Chang C 2001 Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. PNAS 98 7200-7205. (doi:10.1073/pnas.121173298)
63. Liu P, Cheng H, Roberts TM & Zhao JJ 2009 Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery 8 627-644. (doi:10.1038/nrd2926)
64. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW et al. 2011 PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clinical Cancer Research 17 6563-6573. (doi:10.1158/1078-0432. CCR-11-1244)
65. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K et al. 2008 Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent In vivo antitumor activity. Molecular Cancer Therapeutics 7 1851-1863. (doi:10.1158/1535-7163.MCT- 08-0017)
66. Maira M, Schnell C, Lollini P, Chouaid C, Schmid P, Nanni P, Lam D, Di Tomaso E, Massacesi C & Rodon J 2012a Preclinical and preliminary clinical activity of NVP-BKM120, an oral pan-class I PI3K inhibitor, in the brain. Annals of Oncology 23 abstract 1675P.
67. Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M et al. 2012b Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Molecular Cancer Therapeutics 11 317-328. (doi:10.1158/1535-7163.MCT-11-0474)
68. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR et al. 2004 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Medicine 10 594-601. (doi:10.1038/nm1052)
69. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E, Ubezio P & Broggini M 2011 Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Research 71 4573-4584. (doi:10.1158/0008-5472.CAN-10-4322)
70. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Basecke J et al. 2011 Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. Journal of Cellular Physiology 226 2762-2781. (doi:10.1002/jcp.22647)
71. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J & Sawyers CL 2004 HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 517-527. (doi:10.1016/j.ccr.2004.09.031)
72. Mellinghoff IK, Cloughesy TF & Mischel PS 2007 PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clinical Cancer Research 13 378-381. (doi:10.1158/1078-0432.CCR-06-1992)
73. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447-4454. (doi:10.1158/0008-5472.CAN-08-0249)
74. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL & Corey E 2008 RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 68 861-871. (doi:10.1002/pros.20752)
75. Morikawa Y, Koike H, Sekine Y, Matsui H, Shibata Y, Ito K & Suzuki K 2012 Rapamycin enhances docetaxel-induced cytotoxicity in a androgenindependent prostate cancer xenograft model by survivin downregulation. Biochemical and Biophysical Research Communications 419 584-589. (doi:10.1016/j.bbrc.2012.02. 089)
76. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS & Montgomery RB 2011 Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research 17 5913-5925. (doi:10.1158/1078-0432.CCR-11-0728)
77. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N et al. 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 449-456. (doi:10.1016/S0140-6736(08)61039-9)
78. Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, Plaisier S, Garraway IP, Huang J, Graeber TG et al. 2011 Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19 792-804. (doi:10.1016/j.ccr.2011.05.006)
79. Mulholland DJ, Kobayashi N, Ruscetti M, Zhi A, Tran LM, Huang J, Gleave M & Wu H 2012 Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Research 72 1878-1889. (doi:10.1158/0008-5472.CAN-11-3132)
80. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM et al. 2012 Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU International 110 1729-1735. (doi:10.1111/j.1464-410X.2012. 11456.x)
81. Nanni P, Nicoletti G, Palladini A, Croci S, Murgo A, Ianzano ML, Grosso V, Stivani V, Antognoli A, Lamolinara A et al. 2012 Multiorgan metastasis of human HER-2(C) breast cancer in Rag2(K/K);Il2rg(K/K) mice and treatment with PI3K inhibitor. PLoS ONE 7 e39626. (doi:10.1371/journal.pone.0039626)
82. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL et al. 2006 mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Research 66 1500-1508. (doi:10.1158/0008-5472.CAN-05-2925)
83. Pan C, Robles D, D'Abronzo L, Beggs RE, deVere-White R, Lara P & Ghosh PM 2012 Synergistic effects of everolimus and bicalutamide in castration-resistant prostate cancer: results from a phase I/II clinical trial [abstract]. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, Illinois. Philadelphia (PA): AACR abstract 5750.
84. Parker C, Heinrich D, O'Sullivan JM, Fossa SD, Chodacki A, Demkow T, Logue JP, Seke M, Widmark A, Johannessen DC et al. 2012 Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. Journal of Clinical Oncology 30 abstract 8.
85. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS & Sabatini DM 2009 DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137 873-886. (doi:10.1016/j.cell.2009.03.046)
86. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine 351 1513-1520. (doi:10.1056/NEJMoa041318)
87. Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B & Toner GC 2009 An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. American Journal of Clinical Oncology 32 338-341. (doi:10.1097/COC.0b013e31818b946b)
88. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J, Lee MJ, Chung EJ, Trepel JB, Sparreboom A et al. 2005 A phase II study of perifosine in androgen independent prostate cancer. Cancer Biology & Therapy 4 1133-1137. (doi:10.4161/cbt.4.10.2064)
89. Pourmand G, Ziaee AA, Abedi AR, Mehrsai A, Alavi HA, Ahmadi A & Saadati HR 2007 Role of PTEN gene in progression of prostate cancer. Urology Journal 4 95-100.
90. Prawettongsopon C, Asawakarn S & Suthiphongchai T 2009 Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002. Oncology Research 17 301-309. (doi:10.3727/096504009787721195)
91. Qian DZ, Rademacher BL, Pittsenbarger J, Huang CY, Myrthue A, Higano CS, Garzotto M, Nelson PS & Beer TM 2010 CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxelinduced cytotoxicity. Prostate 70 433-442. (doi:10.1002/pros.21077)
92. Rathkopf DE, Danila DC, Morris MJ, Slovin SF, Borwick LS, Momen L, Curley T, Arauz G, Larson SM, Fleisher M et al. 2011 Anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody cixutumumab (cix) plus mTOR inhibitor temsirolimus (tem) in metastatic castrationresistant prostate cancer (mCRPC): results of a phase I pilot study. Journal of Clinical Oncology 29 abstract e15081.
93. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven BA, Di Stefano F et al. 2009 Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics 8 1725-1738. (doi:10.1158/1535-7163.MCT-08-1200)
94. Reid AH, Attard G, Ambroisine L, Fisher G, Kovacs G, Brewer D, Clark J, Flohr P, Edwards S, Berney DM et al. 2010 Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. British Journal of Cancer 102 678-684. (doi:10.1038/sj.bjc. 6605554)
95. Renner O, Blanco-Aparicio C, Grassow M, Canamero M, Leal JF & Carnero A 2008 Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Research 68 9643-9653. (doi:10. 1158/0008-5472.CAN-08-1539)
96. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K et al. 2008 Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Research 68 2366-2374. (doi:10.1158/0008-5472.CAN-07-5783)
97. Rini BI & Small EJ 2002 Hormone-refractory prostate cancer. Current Treatment Options in Oncology 3 437-446. (doi:10.1007/s11864-002-0008-1)
98. Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC, Poulikakos PI, Scaltriti M, Moskatel E, Baselga J, Guichard S & Rosen N 2011 mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. Cancer Discovery 1 248-259. (doi:10.1158/2159-8290. CD-11-0085)
99. Sarbassov DD, Guertin DA, Ali SM & Sabatini DM 2005 Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 1098-1101. (doi:10.1126/science.1106148)
100. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL & Sabatini DM 2006 Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Molecular Cell 22 159-168. (doi:10.1016/j.molcel.2006.03.029)
101. Sarker D, Reid AH, Yap TA & de Bono JS 2009 Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clinical Cancer Research 15 4799-4805. (doi:10.1158/1078-0432.CCR-08-0125)
102. Schayowitz A, Sabnis G, Goloubeva O, Njar VC & Brodie AM 2010 Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR. British Journal of Cancer 103 1001-1007. (doi:10.1038/sj.bjc.6605882)
103. Scher HI, Morris MJ, Basch E & Heller G 2011 End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. Journal of Clinical Oncology 29 3695-3704. (doi:10.1200/JCO. 2011.35.8648)
104. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND et al. 2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187-1197. (doi:10.1056/NEJMoa1207506)
105. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV et al. 2007 Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clinical Cancer Research 13 2023-2029. (doi:10.1158/1078-0432.CCR-06-2701)
106. Shapiro G, LoRusso P, Kwak EL, Cleary JM, Musib L, Jones C, deCrespigny A, Belvin M, McKenzie M, Gates MR et al. 2011 Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a firstin-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors [abstract]. Journal of Clinical Oncology 29 abstract 3005.
107. Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012 10-29. (doi:10.3322/caac.20138)
108. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, von Guggenberg E, Neher A, Bonn GK, Huber LA et al. 2008 Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 8 4521-4533. (doi:10.1002/pmic. 200800113)
109. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB & Kabbinavar FF 2007 A phase II trial of gefitinib in patients with nonmetastatic hormone-refractory prostate cancer. BJU International 100 765-769. (doi:10.1111/j.1464-410X.2007.07121.x)
110. Sparks CA & Guertin DA 2010 Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene 29 3733-3744. (doi:10.1038/onc.2010.139)
111. Sridhar SS, Hotte SJ, Chin JL, Hudes GR, Gregg R, Trachtenberg J, Wang L, Tran-Thanh D, Pham NA, Tsao MS et al. 2010 A multicenter phase II clinical trial of lapatinib (GW57) in hormonally untreated advanced prostate cancer. American Journal of Clinical Oncology 33 609-613. (doi:10.1097/COC. 0b013e3181beac33)
112. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al. 2010 Integrative genomic profiling of human prostate cancer. Cancer Cell 18 11-22. (doi:10.1016/j.ccr.2010.05.026)
113. Templeton A, Rothermundt C, Cathomas R, Baertschi D, Droege C, Gautschi O, Borner MM, Fechter E, Stenner F, Winterhalder RC et al. 2011 Everolimus as first-line therapy in nonrapidly progressive metastatic castration-resistant prostate cancer (mCRPC): a multicenter phase II trial (SAKK 08/08). Journal of Clinical Oncology 29 abstract 4588.
114. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY et al. 2009 AKTindependent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16 21-32. (doi:10.1016/j.ccr.2009.04.012)
115. Von Hoff DD, LoRusso P, Tibes R, Shapiro G, Weiss GJ, Ware JA, Fredrickson J, Mazina KE, Levy GG & Wagner AJ 2010 A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. Journal of Clinical Oncology 28 abstract 2541. (doi:10.1200/JCO.2009.26.5983)
116. Wagner AJ, Bendell JC, Dolly S, Morgan JA, Ware JA, Fredrickson J, Mazina KE, Lauchle JO, Burris HA & De Bono JS 2011 A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. Journal of Clinical Oncology 29 abstract 3020.
117. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J et al. 2011 GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Molecular Cancer Therapeutics 10 2426-2436. (doi:10.1158/1535-7163.MCT-11-0446)
118. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G,
119. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K & Sawyers CL 2010 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. PNAS 107 16759-16765. (doi:10.1073/pnas. 1012443107)
120. Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Haferkamp A & Blaheta RA 2011a Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Letters 301 17-28. (doi:10.1016/j.canlet.2010.11.003)
121. Wedel S, Hudak L, Seibel JM, Makarevic J, Juengel E, Tsaur I, Waaga-Gasser A, Haferkamp A & Blaheta RA 2011b Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer 11 375. (doi:10.1186/1471-2407-11-375)
122. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH & Hung MC 2000 HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Research 60 6841-6845.
123. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT & Grigson G 2011 A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urologic Oncology 31 82-86. (doi:10.1016/j.urolonc.2010.09.018)
124. Wu L, Birle DC & Tannock IF 2005 Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Research 65 2825-2831. (doi:10.1158/0008- 5472.CAN-04-3137)
125. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ & Holz MK 2009 S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. Journal of Biological Chemistry 284 6361-6369. (doi:10.1074/jbc.M807532200)
126. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG et al. 2011 Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 364 514-523. (doi:10.1056/NEJMoa1009290)
127. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Angagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF et al. 2009 Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Research 69 7466-7472. (doi:10.1158/0008-5472.CAN-08- 4385)
128. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L & Crawford ED 2004 The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 332-337. (doi:10.1002/pros.20065)